The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full approval, sending the drugmaker's shares soaring and easing concerns around the ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

In a reversal from statements a day prior, the Wisconsin Department of Health Services now says it will release COVID relief funds that President Donald Trump's administration sought to cancel ...

Just last week, the US Food and Drug Administration delayed a decision on full approval of Novavax’s Covid-19 vaccine even though it was on track to be cleared, leaving many public health ...

The rise in Novavax’s shares can be attributed to the stock price recovery after it fell for 8 consecutive sessions. Despite the FDA’s delay in approving the company’s protein-based COVID-19 ...